Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ZXS
|
|||
| Former ID |
DIB009529
|
|||
| Drug Name |
MAXY-G34
|
|||
| Synonyms |
Maxy-G21; MAXY-G-CSF; G-CSF agonist (neutropenia, leukopenia), Maxygen
Click to Show/Hide
|
|||
| Indication | Neutropenia [ICD-11: 4B00.0; ICD-9: 288] | Phase 2 | [1] | |
| Company |
Maxygen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Granulocyte colony-stimulating factor receptor (G-CSF-R) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00501332) Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy. U.S. National Institutes of Health. | |||
| REF 2 | Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.